BioLineRx Cost Of Revenue vs Net Income From Continuing Ops Analysis
BLRX Stock | USD 0.24 0.01 4.00% |
BioLineRx financial indicator trend analysis is way more than just evaluating BioLineRx prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioLineRx is a good investment. Please check the relationship between BioLineRx Cost Of Revenue and its Net Income From Continuing Ops accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.
Cost Of Revenue vs Net Income From Continuing Ops
Cost Of Revenue vs Net Income From Continuing Ops Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioLineRx Cost Of Revenue account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have almost no relationship.
The correlation between BioLineRx's Cost Of Revenue and Net Income From Continuing Ops is 0.19. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of BioLineRx, assuming nothing else is changed. The correlation between historical values of BioLineRx's Cost Of Revenue and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of BioLineRx are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Cost Of Revenue i.e., BioLineRx's Cost Of Revenue and Net Income From Continuing Ops go up and down completely randomly.
Correlation Coefficient | 0.19 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Cost Of Revenue
Cost of Revenue is found on BioLineRx income statement and represents the costs associated with goods and services BioLineRx provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Net Income From Continuing Ops
Most indicators from BioLineRx's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioLineRx current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.At this time, BioLineRx's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 22.8 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (2.05) in 2024.
BioLineRx fundamental ratios Correlations
Click cells to compare fundamentals
BioLineRx Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioLineRx fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 53.6M | 47.3M | 81.4M | 76.4M | 63.9M | 53.7M | |
Other Current Liab | 7K | 1.4M | 1.2M | 1.3M | 3.4M | 3.5M | |
Total Current Liabilities | 12.0M | 10.6M | 9.7M | 10.7M | 30.9M | 32.4M | |
Total Stockholder Equity | 33.4M | 22.0M | 68.1M | 50.8M | 13.2M | 12.6M | |
Other Liab | 323K | 658K | 10.2M | 1.9M | 2.1M | 2.2M | |
Accounts Payable | 7.8M | 5.9M | 5.6M | 7.0M | 10.9M | 11.4M | |
Cash | 5.3M | 16.8M | 13.0M | 10.6M | 4.3M | 8.0M | |
Long Term Debt | 7.8M | 5.8M | 2.7M | 8.6M | 6.6M | 3.6M | |
Common Stock Shares Outstanding | 9.8M | 16.9M | 44.2M | 51.6M | 64.2M | 67.4M | |
Short Term Investments | 22.2M | 5.8M | 44.1M | 40.5M | 38.7M | 28.6M | |
Other Current Assets | 108K | 152K | 127K | 198K | 1.5M | 1.5M | |
Total Liab | 20.2M | 25.3M | 13.3M | 25.5M | 50.7M | 53.2M | |
Intangible Assets | 21.9M | 21.7M | 21.7M | 21.9M | 14.9M | 10.4M | |
Common Stock | 4.7M | 9.9M | 21.1M | 27.1M | 31.4M | 32.9M | |
Property Plant Equipment | 2.2M | 3.5M | 2.7M | 2.3M | 2.6M | 2.1M | |
Short Long Term Debt Total | 10.5M | 7.7M | 4.7M | 12.3M | 11.6M | 12.2M | |
Property Plant And Equipment Net | 3.5M | 2.7M | 2.3M | 2.5M | 1.9M | 2.2M | |
Net Debt | 5.2M | (9.1M) | (8.3M) | 1.7M | 7.3M | 7.7M | |
Retained Earnings | (248.0M) | (278.0M) | (305.0M) | (330.0M) | (390.6M) | (371.1M) | |
Non Current Assets Total | 25.4M | 24.4M | 24.0M | 24.4M | 16.7M | 13.7M | |
Non Currrent Assets Other | 56K | 25.4M | 21.4M | (1.0) | (1.15) | (1.09) | |
Cash And Short Term Investments | 27.5M | 22.6M | 57.1M | 51.1M | 43.0M | 39.3M | |
Net Receivables | 613K | 141K | 142K | 721K | 708K | 430.0K | |
Common Stock Total Equity | 2.8M | 3.1M | 4.7M | 9.9M | 11.4M | 11.9M | |
Liabilities And Stockholders Equity | 53.6M | 47.3M | 81.4M | 76.4M | 63.9M | 54.1M | |
Non Current Liabilities Total | 8.2M | 14.6M | 3.6M | 14.9M | 19.9M | 20.8M | |
Other Stockholder Equity | 265.9M | 279.2M | 339.3M | 339.0M | 355.5M | 255.4M | |
Property Plant And Equipment Gross | 3.5M | 2.7M | 6.8M | 2.5M | 7.4M | 7.8M | |
Total Current Assets | 28.2M | 22.9M | 57.4M | 52.0M | 47.2M | 40.4M | |
Accumulated Other Comprehensive Income | 10.7M | 10.9M | 11.7M | 13.3M | 17.0M | 10.8M | |
Short Term Debt | 2.9M | 3.3M | 2.9M | 2.4M | 3.7M | 3.9M | |
Net Tangible Assets | 19.3M | 11.5M | 316K | 46.4M | 41.7M | 22.1M | |
Short Long Term Debt | 2.7M | 3.1M | 2.8M | 1.5M | 3.1M | 1.8M | |
Net Invested Capital | 41.9M | 27.9M | 70.8M | 61.0M | 23.0M | 37.5M | |
Net Working Capital | 16.2M | 12.2M | 47.7M | 41.3M | 16.3M | 23.2M | |
Capital Stock | 4.7M | 9.9M | 21.1M | 27.1M | 31.4M | 17.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.